| Kiadis–Leucadia: investor conference, 201906 supply service Kiadis presents at Jefferies 2019 Global Healthcare Conference NYC |
2019-06-04 |
| Bruker Corp–PreOmics: sample preparation technology, 201905– collab developm + marketing PreOmics iST sample preparation on timsTOF Pro MS system |
2019-05-31 |
| Medical Univ South Carolina–Bruker Corp: mass spectrometer, 201905 supply existent timsTOF fleX system early customer Proteomics Center at Med Univ SC |
2019-05-31 |
| Kiadis–SEVERAL: investment, 201905 private placment €27.6m with 3.68m new shares at €7.5/share |
2019-05-30 |
| Bayer–Roche: molecular companion diagnostics, 201905– collab ww €na developm + commercialisation o fNGS-based CDx in oncology |
2019-05-29 |
| Cubuslab–Labfolder: investment, 201905 acquisition merger of Cubuslab Gmbh + Labfolder GmbH + new name Labforward GmbH |
2019-05-22 |
| Kiadis–Be The Match: cell therapy, 201905– collab logistical + technological solutions for ATIR101 developm in US + CA by Be The Match |
2019-05-22 |
| JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion |
2019-05-20 |
| Just Biotherapeutics (US)–Evotec: investment, 201905– acquisition 100% for $60m upfront + $30m upfront |
2019-05-20 |
| LifeArc–CPPIB: pembrolizumab, 201905 acquisition of portion of Keytruda royalty interests for $1.297b by CPPIB Credit Europe Sàrl |
2019-05-20 |
| Storm Therapeutics–Pfizer: investment, 201905 financing round Series A extension totalling £14m incl existing investor Pfizer Ventures |
2019-05-20 |
| Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS |
2019-05-20 |
| Avantor–SEVERAL: investment, 201905 IPO $3.8b at NYSE with Avantor continuing to be largest shareholder |
2019-05-17 |
| LabCentral–Harrison Street: business park, 201905 supply service existent LabCentral is anchor tenant at Osborn Triangle lab complex in Cambridge MA |
2019-05-17 |
| MIT–Harrison Street: business park, 201905 acquisition of Osborn Triangle complex by Harrision Street + Bulfinch from MIT with MIT retaining interest |
2019-05-17 |
| Novartis–Harrison Street: business park, 201905 supply service existent Novartis 1 of 3 anchor tenants at Osborn Triangle lab complex in Cambridge MA |
2019-05-17 |
| Pfizer–Harrison Street: business park, 201905 supply service existent Pfizer is 1 of 3 anchor tenants at Osborn Triangle lab complex in Cambridge MA |
2019-05-17 |
| DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP |
2019-05-16 |
| Inovio–Qiagen: molecular companion diagnostics, 201905– collab developm of CDx for VGX-3100 DNA-based immunotherapy for cervical dysplasia |
2019-05-16 |
| Roche–AbbVie: ventoclax, 201905 collab existent joint commercialisation in US as Venclexta by AbbVie + Genentech |
2019-05-16 |
| Navan Technologies–Amgen: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–Hemi Ventures: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–High-Tech Gründerfonds: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–SEVERAL: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–Stanford Univ: cell therapy technology, 201905 license excl existent to NanoStraw technology platform |
2019-05-15 |
| Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders |
2019-05-15 |
| MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego |
2019-05-08 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| Confo Therapeutics–Perceptive Advisors: investment, 201905 financing round Series A totalling €30m incl new + co-investor Perceptive Advisors |
2019-05-07 |
| Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners |
2019-05-07 |
| Confo Therapeutics–Univ Michigan: investment, 201905 financing round Series A totalling €30m incl existing + co-investor MINTS |
2019-05-07 |
| Confo Therapeutics–V-Bio Ventures: investment, 201905 financing round Series A totalling €30m incl existing + co-investor V-Bio Ventures |
2019-05-07 |
| Confo Therapeutics–VIB: investment, 201905 financing round Series A totalling €30m incl existing + co-investor VIB |
2019-05-07 |
| Merck (DE)–DyNAbind: drug discovery technology, 201905 collab existent marketing of DEL discovery kit with Merck KGaA |
2019-05-07 |
| Northwestern Univ–DyNAbind: drug discovery technology, 201905 collab existent with Northwestern Univ Chicago |
2019-05-07 |
| Promethera–SEVERAL: investment, 201905 financing round Series D €39.7m co-led by Itochu Corp + Shinsei Capital Partners |
2019-05-07 |
| Promethera–Shinsei Capital: investment, 201905 financing round Series D totalling €39.7m incl new + co-lead investor Shinsei Capital Partners |
2019-05-07 |
| Abide Therapeutics–Lundbeck: investment, 201905– acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
| Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS |
2019-05-03 |
| Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC |
2019-05-03 |
| AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO |
2019-05-02 |
| National Cancer Center (JP)–Fluidigm: mass cytometry, 201905 supply existent use of Hyperion Imaging System for I-O research |
2019-05-02 |
| Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson |
2019-05-02 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| SomaLogic–Agilent: oligo microarrays, 201904– supply €na multi-year custom oligo arrays for SOMAscan assay |
2019-04-30 |
| 908 Devices–ARCH Venture: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor ARCH Ventures |
2019-04-29 |
| 908 Devices–Casdin Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Casdin Capital |
2019-04-29 |
| 908 Devices–Northpond Ventures: investment, 201904 financing round Series E totalling $17.5m incl new + lead investor Northpond Ventures |
2019-04-29 |
| 908 Devices–Razor’s Edge Ventures: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Razor’s Edge Ventures |
2019-04-29 |
| 908 Devices–Sands Capital: investment, 201904 financing round Series E totalling $17.5m incl new + co-investor Sands Capital Ventures |
2019-04-29 |
| 908 Devices–Saudi Arabia: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Saudi Aramco Energy Ventures |
2019-04-29 |
| 908 Devices–Schlumberger: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Schlumberger |
2019-04-29 |
| 908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures |
2019-04-29 |
| 908 Devices–Tao Capital Partners: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Tao Capital Partners |
2019-04-29 |
| Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners |
2019-04-29 |
| JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen |
2019-04-29 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| LabCorp–Biocartis: molecular diagnostics, 201904– collab ww €na offering of Idylla platform + oncology assays by Covance for drug development |
2019-04-23 |
| Sherlock Biosciences–Baidu Ventures: investment, 201903–201904 financing round Series A totalling $31m incl co-lead investor Baidu Ventures |
2019-04-23 |
| Sherlock Biosciences–Northpond Ventures: investment, 201903–201904 financing round Series A totalling $31m incl co-lead investor Northpond Ventures |
2019-04-23 |
| Sherlock Biosciences–Open Philanthropy Project: investment, 201903–201904 financing round Series A totalling $31m incl co-investor OPP |
2019-04-23 |
| DSM–Panacea BioMatx: nutripharmaceuticals, 201904– collab excl marketing + sales of personalised nutrition products of Panaceutics by DSM |
2019-04-22 |
| Poseida Therapeutics–Aisling Capital: investment, 201904 financing round Series C totalling $142m incl new + co-investor Aisling Capital Management |
2019-04-22 |
| Poseida Therapeutics–Canale Communications: public relations, 201904 service existent by Canale |
2019-04-22 |
| Poseida Therapeutics–Longitude Capital: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Longitude Capital |
2019-04-22 |
| Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp |
2019-04-22 |
| Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG |
2019-04-22 |
| Poseida Therapeutics–Pentwater Capital: investment, 201904 financing round Series C totalling $142m incl new + co-investor Pentwater Capital |
2019-04-22 |
| Poseida Therapeutics–Perceptive Advisors: investment, 201904 financing round Series C totalling $142m incl new + co-investor Perceptive Advisors |
2019-04-22 |
| Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m |
2019-04-22 |
| Poseida Therapeutics–Tavistock: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Boxer Capital LLC |
2019-04-22 |
| Poseida Therapeutics–Vivo Capital: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Vivo Capital |
2019-04-22 |
| Arrakis Therapeutics–Advent Venture Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Advent LS |
2019-04-18 |
| Arrakis Therapeutics–Alexandria Real Estate: investment, 201904 financing round Series B totalling $75m incl new + co- investor Alexandria Ventures |
2019-04-18 |
| Arrakis Therapeutics–Alphabet: investment, 201904 financing round Series B totalling $75m incl new + co- investor GV |
2019-04-18 |
| Arrakis Therapeutics–Canaan Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Canaan Partners |
2019-04-18 |
| Arrakis Therapeutics–Celgene: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Celgene Corp |
2019-04-18 |
| Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments |
2019-04-18 |
| Arrakis Therapeutics–Nextech Invest: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest |
2019-04-18 |
| Arrakis Therapeutics–Omega Advisors: investment, 201904 financing round Series B totalling $75m incl new + co- investor Omega Funds |
2019-04-18 |
| Arrakis Therapeutics–Osage Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Osage University Partners |
2019-04-18 |
| Arrakis Therapeutics–PERSON: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Estate of Henri Termeer |
2019-04-18 |
| Arrakis Therapeutics–Pfizer: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Pfizer Ventures |
2019-04-18 |
| Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest |
2019-04-18 |
| Arrakis Therapeutics–VenBio: investment, 201904 financing round Series B totalling $75m incl co-lead investor VenBio Partners |
2019-04-18 |
| Arrakis Therapeutics–WuXi PharmaTech: investment, 201904 financing round Series B totalling $75m incl new + co- investor WuXi AppTec Venture Fund |
2019-04-18 |
| CytoSen Therapeutics–Kiadis: investment, 201904– acquisition merger in shares with 1.94m shares (7.4%) upfront plus 5.82 shares milestones |
2019-04-17 |
| Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–Silicon Valley Bank: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO |
2019-04-17 |
| Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO |
2019-04-17 |
| Bruker Corp–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML |
2019-04-16 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
